SCIENCE

Science

Our scientific approach focuses on the targeted delivery of therapeutic agents.

Most drugs do not selectively accumulate at site of disease; for example most chemotherapy drugs used in oncology tend to accumulate in healthy tissues at significantly higher concentrations than at tumor sites.

Since the formation of new blood vessels (angiogenesis) is rare in the healthy human adult but is closely associated with various malignant or inflammatory disorders, and since newly formed blood vessels are different at the molecular level from mature blood vessels, our mission has been to become the leaders in the niche field of the targeted delivery of drugs to new blood vessels (Vascular Targeting).

In house cutting-edge platform technologies are exploited to implement the following discovery and development strategy:

Identification of molecular abnormalities of blood vessels at disease sites using novel proteomic strategies

Click to enlarge

1

Identification of molecular abnormalities of blood vessels at disease sites using novel proteomic strategies

Generation of specific ligands to these targets from proprietary Antibody Libraries or DNA-Encoded Chemical Libraries

Click to enlarge

2

Generation of specific ligands to these targets from proprietary Antibody Libraries or DNA-Encoded Chemical Libraries

Confirm by nuclear medicine techniques if ligand (antibody or chemical entity) accumulates in vivo to vascular structures at disease sites

Click to enlarge

3

Confirm by nuclear medicine techniques if ligand (antibody or chemical entity) accumulates in vivo to vascular structures at disease sites

Arm targeting ligand with payloads such as pro- or anti-inflammatory cytokines (creating Immunocytokines) or drugs (creating Antibody Drug Conjugates or Small Molecule Drug Conjugates

Click to enlarge

4

Arm targeting ligand with payloads such as pro- or anti-inflammatory cytokines (creating Immunocytokines) or drugs (creating Antibody Drug Conjugates)

Develop vascular-targeting armed products in controlled clinical trials. In this patient, the diseased cancer lesion (bright circle) in the left panel is eliminated by the treatment

Click to enlarge

5

Develop vascular-targeting armed products in controlled clinical trials. In this patient, the diseased cancer lesion (bright circle) in the left panel is eliminated by the treatment